Research Letters
First-dose effects with intravitreal aflibercept in wet age-related macular degeneration: a post-hoc analysis of VIEW-1 and VIEW-2 phase 3 studies
A post-hoc analysis of data from the VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD (VIEW) studies1 was conducted after publication of best-corrected visual acuity (BCVA) data from the Development of Macular Atrophy in Patients with Neovascular Age-Related Macular Degeneration: A Comparison of Ranibizumab and Aflibercept (RIVAL) study. BCVA results from RIVAL suggested (although not a predefined endpoint) a delayed improvement with intravitreal aflibercept (IVT-AFL) versus ranibizumab (RBZ) in treatment-naïve patients with neovascular age-related macular degeneration (nAMD).National survey of Canadian Retina Society members on guidelines for ophthalmic care during the COVID-19 crisis: Canadian Retina Research Network (CR2N) COVID-19 Steering Committee analysis
An anonymous survey was designed by the Canadian Retina Research Network coronavirus disease 2019 (COVID-19) Steering Committee to assess awareness of, confidence in, and adherence to recent guidelines released by the Canadian Ophthalmology Society (COS) and Canadian Retina Society (CRS) for ophthalmic care during the COVID-19 pandemic.1,2 The survey was pilot-tested and validated with 9 content experts. It was then distributed via email to physician members of the CRS in May 2020 with one reminder email to maximize response rate.
